Kovirvin (AB21 D+) is a next-generation, comprehensive probiotic featuring well-researched lactobacilli. It effectively shortens the duration of intestinal disorders and rapidly eliminates pathogenic bacteria during intestinal infections. Kovirvin reduces intestinal inflammation and restores gut microbiota balance, particularly during and after antibiotic use. Uniquely, Kovirvin (AB21 D+) is the first probiotic to demonstrate antiviral efficacy in a large-scale clinical trial, offering protection against respiratory viral infections (including RSV, influenza, and COVID-19) and reducing symptom duration and transmission risk. Recommended for seasonal illnesses, colds, and during vaccination. Featured in clinical guidelines from the World Gastroenterology Organisation, the Russian Gastroenterological Association, and the Scientific Society of Gastroenterologists of Russia, and the Infectious Disease Clinical Guidelines. Awarded the prestigious "Probiotic of the Year 2022" international award. Easy to use: 1 capsule daily for preventative gut and respiratory health, 2 capsules daily at the first sign of illness. High safety profile. Gluten-free, lactose-free, and GMO-free. GMP certified.
US: temporary delays — postal services aligning new import rules, 
EU: 1–2 weeks, 🌍 Worldwide: 1–4 weeks ✈️